Giesel FL, et al. - Biochemical recurrence (BCR) after local treatment is a concern for prostate cancer patients, so experts evaluated the imaging potential of 18F-PSMA-1007 in subjects with biochemical recurrence (BCR). Data revealed that 18F-PSMA-1007 PET/CT identified lesions in 75% patients. While comparing the tracer uptake in 18F-PSMA-1007–positive lesions 1 vs 3 hours after injection, a notable variation was discovered. Therefore, it was demonstrated that 18F-PSMA-1007 PET/CT had a high potential for localization of recurrent disease in prostate cancer patients with BCR.